Prevention of UV-induced Infections and Carcinogenic Skin Alterations in Immunosuppressed Outpatients After Solid Organ Transplantations

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2013 by Spirig Pharma Ltd..
Recruitment status was  Active, not recruiting
Information provided by (Responsible Party):
Spirig Pharma Ltd. Identifier:
First received: February 9, 2012
Last updated: October 24, 2013
Last verified: October 2013
The purpose of this trial is to investigate the prevention of actinic keratoses and squamous cell carcinomas by local application of MD-3511356 in comparison to standard sun protection measures in immunosuppressed solid organ transplant recipients.

Condition Intervention Phase
Actinic Keratoses
Squamous Cell Carcinomas
Device: MD-3511356
Other: Standard Sun Protection Measures
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: An Open, Multicentre, Randomised, Inter-individual Comparative, Prospective Clinical Trial With MD-3511356 Versus Standard Sun Protection Measures in Immunosuppressed Outpatients After Solid Organ Transplantations for the Prevention of UV-induced Infections and Carcinogenic Skin Alterations.

Resource links provided by NLM:

Further study details as provided by Spirig Pharma Ltd.:

Primary Outcome Measures:
  • Number of new clinically diagnosed actinic keratoses or squamous cell carcinomas [ Time Frame: 2 Years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Number of patients with new actinic keratoses, squamous cell carcinomas or basal cell carcinomas [ Time Frame: 2 Years ] [ Designated as safety issue: No ]

Estimated Enrollment: 300
Study Start Date: November 2010
Estimated Study Completion Date: June 2015
Estimated Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Standard Sun Protection Measures Other: Standard Sun Protection Measures
Self-provided commercially available sunscreen products, corresponding to the dosage recommendations on the product.
Experimental: MD-3511356 Device: MD-3511356
Every morning MD-3511356 should be applied liberally to those skin areas exposed to direct sunlight before exposing to the sun.


Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Out-Patients of either sex aged ≥ 40 years
  • Life-expectancy of 2 years at minimum
  • Solid organ-transplant recipients who received a kidney (including pancreas), liver, lung, or heart transplant
  • Patients treated for 5 years with an immunosuppressant medication
  • Severe sun damage of the skin
  • Multiple actinic keratoses (2-5 lesions) and/or multiple dysplastic naevi
  • No present squamous cell carcinoma, basal cell carcinoma or malignant melanoma; but history of cutaneous/cutaneous invasive malignancy with restitutio ad integrum is allowed
  • Patients who are able to understand and provide written informed consent to participate in the clinical trial (signed informed consent) according to ICH GCP

Exclusion Criteria:

  • Non-Caucasian
  • Absence of sun damage i.e. no signs of AK
  • Multi-organ transplantation (exception: simultaneous transplantation of kidney and pancreas)
  • Evidence of systemic infection, except viral hepatitis, at the time of recruitment
  • Known or supposed systemic malignant tumour or systemic chemotherapy within the last 5 years prior to randomisation
  • Patients participating in a clinical trial within the last four weeks before trial
  • Patients treated with the antitumour/antiangiogenetic immunosuppressant sirolimus, respectively everolimus, or acitretin or any other systemic treatment for AK at the time of randomisation
  • Patients treated with a topical drug for the AK at the time of randomisation (exception: excision or kryotherapy for hyperkeratotic lesions are allowed)
  • Change of the immunosuppression-treatment less than 3 months ago or planned
  • Present or planned interferon therapy (in liver transplant patients with hepatitis B/C)
  • Female patients with childbearing potential with a positive pregnancy test, breast feeding, or female patients with childbearing potential without adequate contraception
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01532453

Medizinische Universität Wien
Wien, Austria
Czech Republic
Charles University Hospital
Plzen, Czech Republic
Hôpital Edouard
Lyon, France
Klinikum der Charité Universitätsmedizin
Berlin, Germany, 10117
Hautklinik am Nationalen Zentrum für Tumorerkrankungen
Heidelberg, Germany
Beaumont Hospital
Dublin, Ireland
Leiden University Medical Center
Leiden, Netherlands
Universitätsspital Zürich, Dermatologische Klinik
Zürich, Switzerland
Başkent University Faculty of Medicine
Ankara, Turkey
United Kingdom
Queen Mary University of London
London, United Kingdom
Sponsors and Collaborators
Spirig Pharma Ltd.
Principal Investigator: Claas Ulrich, MD Klinikum der Charité Universitätsmedizin, Hauttumorzentrum Charité, D-10117 Berlin/Germany
  More Information

No publications provided

Responsible Party: Spirig Pharma Ltd. Identifier: NCT01532453     History of Changes
Other Study ID Numbers: SP 488/2009
Study First Received: February 9, 2012
Last Updated: October 24, 2013
Health Authority: Switzerland: Ethikkommission
Switzerland: Swissmedic
Germany: Ethics Commission
Germany: Federal Institute for Drugs and Medical Devices
France: Institutional Ethical Committee
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Czech Republic: Ethics Committee
Czech Republic: State Institute for Drug Control
Ireland: Irish Medicines Board
Ireland: Medical Ethics Research Committee
United Kingdom: Medicines and Healthcare Products Regulatory Agency
United Kingdom: National Institute for Health Research
Turkey: Ethics Committee
Turkey: Ministry of Health
Austria: Ethikkommission
Austria: Federal Office for Safety in Health Care
Netherlands: Dutch Health Care Inspectorate
Netherlands: Independent Ethics Committee

Additional relevant MeSH terms:
Carcinoma, Squamous Cell
Keratosis, Actinic
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Squamous Cell
Precancerous Conditions
Skin Diseases processed this record on November 25, 2015